#USA #New York #Levi Korsinsky #ADMA Biologics #ASCENIV

Class Action Alert for ADMA Biologics Investors

Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) should take note of an important legal development. A class action lawsuit has been initiated, urging shareholders who purchased securities between August 9, 2024, and March 25, 2026, to come forward. This suit highlights allegations of materially misleading statements purportedly made by the company, especially concerning its revenue reporting practices. The deadline for lead plaintiff applications is set for August 10, 2026.

Background of Allegations

The lawsuit centers around ASCENIV, a product marketed by ADMA which is presumably pivotal for the company’s revenue streams. Reports have surfaced claiming that ADMA engaged in channel stuffing—a practice that involves inflating revenue figures by shipping excess product to distributors, thus artificially creating an appearance of strong demand. While ADMA claimed massive revenue growth of 20% year-over-year, investigative research suggests an actual decline of around 3% in revenue, raising serious concerns about the validity of their financial reports.

In 2025, ASCENIV’s reported net revenues stood at approximately $362.5 million, which, under scrutiny, appear to have been boosted by questionable sales tactics according to the class-action suit. Documentation released from a March 2026 research report contradicts ADMA’s growth claims, prompting a critical examination of the company’s revenue recognition policies.

Examination of Revenue Recognition Practices

The lawsuit posits that ADMA’s methodology for recognizing revenue is fundamentally flawed. By delivering unwanted quantities of ASCENIV to distributors, ADMA could falsely record sales, despite the lack of underlying demand in the market. These sales were accounted for upon delivery, but as subsequent orders from healthcare providers slowed—given reimbursement hurdles—excess inventory began to accumulate. The firm’s internal disclosures maintain that their financial controls were effective, yet this lawsuit claims that those assertions were misleading.

Details of Related Party Disclosures

Compounding the issue, the complaint raises questions about undisclosed sales to Genesis BioPharma Services, an entity linked to ADMA and operating from its corporate headquarters. This relationship, allegedly concealed from investors, may have facilitated the channel stuffing scheme by creating a blurred line between legitimate sales transactions and internal manipulations designed to inflate revenue figures further.

What Should Investors Do?

Affected investors are encouraged to compile documentation, such as brokerage records that detail purchase dates, share amounts, and prices paid, as this information will be critical in demonstrating eligibility for recovery. Interested shareholders should contact Levi & Korsinsky, LLP for a complimentary evaluation of their circumstance. Importantly, this process does not require attendance in court or other direct involvement, minimizing the burden on shareholders while allowing them to pursue potential recovery for their losses.

Conclusion

The present scenario underscores the vital need for transparency and trust within financial markets, particularly in the specialty biologics sector. As this lawsuit unfolds, it raises crucial questions about revenue recognition guidelines and the responsibilities of public companies toward their shareholders. Investors are urged to act swiftly and engage with legal experts to ensure their rights are safeguarded in light of these serious allegations against ADMA Biologics.